Neonc Technologies Holdings Inc (NTHI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.03+5.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NTHI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -68.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NTHI — earnings miss
Dated 2026-08-10
Results of Operations and Financial Condition. On August 10, 2026, NeOnc Technologies Holdings, Inc. (the “Company”) issued a press release reporting second quarter financial results and confirmed that topline results from its fully enrolled Phase 2a NEO100 study will be presented on August 12, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and the information therein is incorporated herein by reference. The information contained in this
Why it matters: The health care sector is maturing. Any signs of revenue growth re-accelerating could benefit NTHI.
Supportive ifHealth care sector revenue growth re-accelerates back toward its highs.
Worry ifHealth care sector revenue growth continues to slow down.
Why it matters: Information on the Series A Preferred Stock may affect future capital use. Clear details may boost investor confidence.
Watch forA press release explains the financial effects of the Series A Preferred Stock issuance.
Also watch forNo new details or bad news about the Series A Preferred Stock issuance.
Why it matters: FDA feedback will guide NeOnc's next steps for NEO100, impacting its development timeline.
Supportive ifFDA agrees with NeOnc's plan for a study on NEO100.
Worry ifFDA has big concerns about the study plan or goals.
Why it matters: Reducing cash operating expenses is key for financial health. Meeting this target shows cost control.
Supportive ifCash operating expenses are at or below $10.1M each year.
Worry ifCash operating expenses are above $10.1M each year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$295 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $1,103 loss on $10,000 · 11.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,345 loss on $10,000 · 73.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The design will decide the next steps for NEO212. This will affect its development.
Supportive ifManagement says the Phase 2 study design for NEO212 is complete.
Worry ifManagement delays or changes the study design a lot.
Why it matters: The full dataset will show how well the treatment works and its safety. Good results could support this method.
Watch forThe company shares the full Phase 2a dataset at a medical meeting. Feedback is positive.
Also watch forThe presentation shows big safety problems or poor results.
Why it matters: The cash position will affect NeOnc's ability to fund ongoing trials and operations. It is critical for their financial health.
Watch forCash and equivalents are over $2 million after the PIPE financing.
Also watch forCash is below $1 million, which may cause liquidity problems.
Why it matters: A Type B meeting with the FDA could set the path for NEO100's approval. This is crucial for patients with no current treatment options.
Supportive ifNeOnc formally requests a Type B meeting with the FDA regarding NEO100's registrational path.
Worry ifNo request is made to the FDA for a Type B meeting on NEO100.
Why it matters: The interim data will show how well NEO100 works for high-grade glioma. Good results may help investors feel more confident.
Supportive ifInterim data shows that over 48.9% of patients in the NEO100 trial are progression-free after six months.
Worry ifInterim data shows that less than 48.9% of patients are progression-free after six months.
Why it matters: Progress on NEO212 could indicate NeOnc's ability to advance its pipeline. FDA feedback will shape the next steps.
Supportive ifNeOnc announces a Type B End-of-Phase 1 meeting with the FDA to discuss NEO212.
Worry ifNo updates or plans are shared regarding NEO212's Phase 2 study design.